| |
| |
|
| Insider
Information: |
Hack Andrew A. F. |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
25,181 |
|
|
Indirect Shares
|
18,379,099 |
|
|
| Direct
Value |
$156,464 |
|
|
|
Indirect Value
|
$35,933,454 |
|
|
| Total
Shares |
18,404,280 |
|
|
| Total
Value |
$36,089,918 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
20
|
7
|
|
Stock
price went up :
|
17
|
3
|
| Stock
price went down : |
3
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
5.7
|
5.7
|
| Percentage
Gain/Loss : |
 61.2%
|
 -72.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Editas Medicine, Inc. |
EDIT |
Chief Financial Officer |
2019-02-04 |
0 |
2017-02-15 |
0 |
Premium* |
|
|
Dynavax Technologies Corp |
DVAX |
|
2023-08-08 |
10,714 |
2023-08-08 |
915,000 |
Premium* |
|
|
Mersana Therapeutics, Inc. |
MRSN |
Director |
2023-06-08 |
14,467 |
2023-06-08 |
8,663,673 |
Premium* |
|
|
Bcls Acquisition Corp. |
BLSA |
Chief Financial Office... |
2020-10-26 |
0 |
2020-10-26 |
487,500 |
Premium* |
|
|
Atea Pharmaceuticals, Inc. |
AVIR |
Director |
2020-11-03 |
0 |
2020-11-03 |
5,615,659 |
Premium* |
|
|
Nuvalent, Inc. |
NUVL |
|
2021-08-02 |
0 |
2024-03-27 |
2,697,267 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NUVL |
Nuvalent, Inc. |
|
– • – |
2024-03-27 |
4 |
S |
$72.31 |
$64,035,959 |
I/I |
(880,000) |
2,697,267 |
0 |
- |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2022-08-15 |
4 |
S |
$14.68 |
$44,040,000 |
I/I |
(3,000,000) |
5,415,000 |
0 |
% |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2021-08-27 |
4 |
S |
$16.22 |
$32,440,000 |
I/I |
(2,000,000) |
8,415,000 |
0 |
% |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2021-08-09 |
4 |
S |
$10.80 |
$24,300,000 |
I/I |
(2,250,000) |
8,524,000 |
0 |
% |
|
| DVAX |
Dynavax Technologies Corp |
|
– • – |
2023-08-08 |
4 |
S |
$14.39 |
$21,585,000 |
I/I |
(1,500,000) |
915,000 |
0 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2020-04-07 |
4 |
B |
$5.59 |
$20,649,463 |
I/I |
3,445,667 |
3,445,667 |
2.1 |
% |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2022-12-06 |
4 |
S |
$11.60 |
$17,400,000 |
I/I |
(1,500,000) |
3,915,000 |
0 |
% |
|
| NUVL |
Nuvalent, Inc. |
Director |
– • – |
2021-08-02 |
4 |
B |
$17.00 |
$12,495,000 |
I/I |
735,000 |
3,428,014 |
2.1 |
- |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2023-05-18 |
4 |
S |
$10.55 |
$10,550,000 |
I/I |
(1,000,000) |
2,915,000 |
0 |
% |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2023-06-14 |
4 |
S |
$12.68 |
$6,340,000 |
I/I |
(500,000) |
2,415,000 |
0 |
% |
|
| AVIR |
Atea Pharmaceuticals, Inc... |
Director |
– • – |
2020-11-03 |
4 |
B |
$24.00 |
$6,000,000 |
I/I |
250,000 |
5,615,659 |
2.1 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2021-12-29 |
4 |
B |
$5.75 |
$5,031,250 |
I/I |
875,000 |
4,570,667 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2022-02-07 |
4 |
B |
$4.42 |
$5,022,724 |
I/I |
1,136,363 |
6,522,030 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2021-12-30 |
4 |
B |
$6.15 |
$5,012,250 |
I/I |
815,000 |
5,385,667 |
2.1 |
% |
|
| DVAX |
Dynavax Technologies Corp |
Director |
– • – |
2020-05-27 |
4 |
B |
$5.00 |
$5,000,000 |
I/I |
1,000,000 |
8,525,000 |
2.1 |
% |
|
| NUVL |
Nuvalent, Inc. |
Director |
– • – |
2022-11-03 |
4 |
B |
$33.50 |
$4,999,976 |
I/I |
149,253 |
3,577,267 |
2.1 |
- |
|
| BLSA |
Bcls Acquisition Corp. |
Chief Financial Officer |
• • • |
2020-10-26 |
4 |
A |
$10.00 |
$4,875,000 |
I/I |
487,500 |
487,500 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2022-04-13 |
4 |
B |
$4.05 |
$2,500,000 |
I/I |
617,284 |
7,737,400 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2022-04-12 |
4 |
B |
$4.18 |
$2,499,880 |
I/I |
598,086 |
7,120,116 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2021-01-08 |
4 |
B |
$18.39 |
$1,839,000 |
I/I |
100,000 |
3,545,667 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2021-01-11 |
4 |
B |
$18.52 |
$1,389,000 |
I/I |
75,000 |
3,620,667 |
2.1 |
% |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2021-01-12 |
4 |
B |
$18.16 |
$1,362,000 |
I/I |
75,000 |
3,695,667 |
2.1 |
% |
|
| EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
• – – |
2018-03-20 |
4 |
AS |
$37.51 |
$1,059,960 |
D/D |
(28,000) |
0 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
Director |
– • – |
2022-05-18 |
4 |
B |
$3.35 |
$707,262 |
I/I |
211,268 |
8,087,400 |
2.1 |
% |
|
| EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
• – – |
2018-03-20 |
4 |
OE |
$6.48 |
$580,080 |
D/D |
28,000 |
22,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
